about
Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.Evaluation of the impact of the cancer therapy everolimus on the central nervous system in miceGene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.Synthesis and biological evaluation of a novel (99m)Tc labeled 2-nitroimidazole derivative as a potential agent for imaging tumor hypoxia.Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis.Selenoprotein T Deficiency Leads to Neurodevelopmental Abnormalities and Hyperactive Behavior in Mice.Seek & Destroy, use of targeting peptides for cancer detection and drug delivery.Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum.Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization.Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel wallsA Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab EmtansinePredicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a DishOctreotide Conjugates for Tumor Targeting and ImagingARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancerProstate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain
P50
Q34359688-D376D874-E7AD-4E3F-AABA-DB04372816E1Q34600979-04CABCFF-828B-49BD-B681-57B6A6A8F2EEQ37046800-F8395F8C-EBAC-4123-8150-6B8E387ECF7AQ39145230-12874C3E-419B-4F3A-ACBD-1BA4EB55240FQ39313143-FC993141-77AF-4088-993E-6A4813C540ABQ46468188-B5711C99-E72E-462E-823B-2A1B8BAF4D82Q47821447-A4B6D44D-1DB8-4163-848C-F80499F22F5FQ48222782-BAEDA2E8-3E4F-484B-B2C4-C4ABF30FB661Q48372089-BB0E5952-055A-47ED-B96F-97C797959FFAQ64911604-B7B0DEE5-2780-4D48-BAF7-6118DF988850Q89694228-9201ADD4-941A-4B6C-B6B7-9E48BCE102EFQ91775021-3BD54C3D-CB65-4580-AD75-0E9A126EC036Q91784407-416D7856-22E6-467E-B8EA-C9D87469979EQ91857399-A183587F-9C32-486C-A480-688A37FC5FAEQ92433720-17047722-5FB8-4AB2-AE24-63B862B559FEQ94540625-5E4D0CD1-55B8-41B6-BB48-2A3BB1CF0A6D
P50
description
Fins onderzoeker
@nl
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Vadim Le Joncour
@ast
Vadim Le Joncour
@en
Vadim Le Joncour
@es
Vadim Le Joncour
@ga
Vadim Le Joncour
@nl
Vadim Le Joncour
@sl
type
label
Vadim Le Joncour
@ast
Vadim Le Joncour
@en
Vadim Le Joncour
@es
Vadim Le Joncour
@ga
Vadim Le Joncour
@nl
Vadim Le Joncour
@sl
prefLabel
Vadim Le Joncour
@ast
Vadim Le Joncour
@en
Vadim Le Joncour
@es
Vadim Le Joncour
@ga
Vadim Le Joncour
@nl
Vadim Le Joncour
@sl
P106
P1153
37021505300
P21
P27
P31
P496
0000-0001-8153-8563